Blood levels of high-sensitivity cardiac troponin T (hs-cTnT), a marker of heart muscle damage, may serve as a prognostic biomarker for adverse events, including death and heart failure, in people with cardiac sarcoidosis, a study in Japan shows. Patients with combined elevated levels of both hs-cTnT and B-type natriuretic…
News
Black people with sarcoidosis have longer delays in referrals to multidisciplinary care, according to a recent study. Treatment of sarcoidosis changed in 78% of patients after a referral, with no significant differences in race, sex, or ethnicity between those who underwent a change to clinical management and those who…
Cutaneous sarcoidosis, a type of sarcoidosis of the skin, may increase the risk of certain blood cancers, a study suggests. The study, “Hematologic diseases in patients with cutaneous sarcoidosis,” was published as a letter to the editor in The Journal of Dermatology, but the researchers acknowledged…
More than one-third of sarcoidosis patients have abnormalities in the small airways, or bronchioles, according to a study in Italy that looked at small-airway inspection and biopsy using ultrathin tubes. The researchers said this procedure could aid in diagnosing sarcoidosis. Small-airway biopsies yielded high rates of granuloma detection: 65.4%…
A global Phase 3 clinical trial evaluating efzofitimod, Atyr Pharma’s investigational therapy, in people with pulmonary sarcoidosis will continue as planned following a third pre-planned interim safety review. An independent data safety and monitoring board (DSMB) examined available safety and tolerability data from all 268 participants enrolled in…
Kinevant Sciences’ experimental therapy namilumab failed to show a benefit for people with chronic, active pulmonary sarcoidosis in a Phase 2 clinical trial involving more than 100 patients. Based on the negative results of the RESOLVE-Lung study (NCT05314517), the company announced it will be discontinuing further development…
The Foundation for Sarcoidosis Research (FSR) is providing $200,000 in grants to fund research into improving the diagnosis and management of cardiac sarcoidosis. The funding comprises two grants specific to cardiac sarcoidosis, each totaling $100,000. This is double the investment the FSR made last year in…
Elevated blood levels of fatty molecules, or lipids — specifically triglycerides and low-density lipoprotein cholesterol (LDL-c), also known as bad cholesterol — may be linked with an increased risk of developing sarcoidosis, while certain lipid-lowering medications may help reduce the risk. That’s according to a study that looked at…
Employees in the U.S. who participate in clinical trials — including those testing treatments for sarcoidosis — and workers also caring for trial participants have access to Family and Medical Leave Act (FMLA) benefits. That’s according to a new letter from the U.S. Department of Labor, sent in response…
Among cardiac sarcoidosis (CS) patients treated with immunosuppressants, those with heart involvement alone can have poorer clinical outcomes than those whose sarcoidosis affects other organs along with the heart, according to a small study. Despite showing less heart inflammation before starting treatment, people with isolated CS (iCS) experienced higher…
Recent Posts
- Final trial data show pulmonary sarcoidosis drug helps patients
- Global sarcoidosis network expands to 55 institutions worldwide
- We need to keep sharing our stories and reject the ‘sickfluencer’ narrative
- Cell-released proteins may predict sarcoidosis treatment response
- Registry study finds heart sarcoidosis outcomes vary by feature
- Critical conversations: Why talking about our medications is essential
- Study challenges theory of microbes as sarcoidosis cause
- FDA, developer align on protocols for trial of pulmonary sarcoidosis drug
- Large study ties sarcoidosis to risk of permanent liver scarring
- Reflecting with gratitude on what sarcoidosis has brought to my life